These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

127 related articles for article (PubMed ID: 26107292)

  • 1. Preclinical assessment of abuse liability of biologics: In defense of current regulatory control policies.
    Gauvin DV; Zimmermann ZJ; Baird TJ
    Regul Toxicol Pharmacol; 2015 Oct; 73(1):43-54. PubMed ID: 26107292
    [TBL] [Abstract][Full Text] [Related]  

  • 2. In further defense of nonclinical abuse liability testing of biologics.
    Gauvin DV; Zimmermann ZJ; Baird TJ
    Regul Toxicol Pharmacol; 2019 Feb; 101():103-120. PubMed ID: 30465804
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The drug discrimination assay: Interpretative value of partial generalization for drug schedule control actions.
    Gauvin DV; Zimmermann ZJ; Code R; Baird TJ
    J Pharmacol Toxicol Methods; 2018; 90():48-57. PubMed ID: 29203450
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The necessity and utility of abuse liability evaluations in human subjects.
    Vocci FJ
    Br J Addict; 1991 Dec; 86(12):1537-42. PubMed ID: 1786484
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Current FDA regulatory guidance on the conduct of drug discrimination studies for NDA review: Does the scientific literature support recent recommendations?
    Gauvin DV; Zimmermann ZJ; Kallman MJ
    Drug Alcohol Depend; 2016 Nov; 168():307-319. PubMed ID: 27629024
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Study design criteria for regulatory-based drug control action: Drug discrimination.
    Gauvin DV; Zimmermann ZJ
    J Pharmacol Toxicol Methods; 2021; 111():107073. PubMed ID: 33965568
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The gold-standard in preclinical abuse liability testing: It's all relative.
    Gauvin DV; Zimmermann ZJ; Baird TJ
    J Pharmacol Toxicol Methods; 2018; 94(Pt 2):36-53. PubMed ID: 30125620
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Guidelines and methodological reviews concerning drug abuse liability assessment.
    Balster RL; Bigelow GE
    Drug Alcohol Depend; 2003 Jun; 70(3 Suppl):S13-40. PubMed ID: 12759195
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Abuse liability assessment for biologic drugs - All molecules are not created equal.
    de Zafra CLZ; Markgraf CG; Compton DR; Hudzik TJ
    Regul Toxicol Pharmacol; 2018 Feb; 92():165-172. PubMed ID: 29199066
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Drug discrimination: A versatile tool for characterization of CNS safety pharmacology and potential for drug abuse.
    Swedberg MD
    J Pharmacol Toxicol Methods; 2016; 81():295-305. PubMed ID: 27235786
    [TBL] [Abstract][Full Text] [Related]  

  • 11. '1996' starting the modern era of biologics regulation: FDA's elimination of establishment licensure and other changes.
    Gamerman GE; Mackler BF; Landa MM
    Biotechnol Appl Biochem; 1997 Jun; 25(3):189-95. PubMed ID: 9198272
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Method of data interpretation for the determination of abuse liability in rodent self-administration studies under the FDA guidance document.
    Gauvin DV; Zimmermann ZJ; Baird TJ
    J Pharmacol Toxicol Methods; 2017 Jul; 86():44-59. PubMed ID: 28315739
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Regulatory administrative databases in FDA's Center for Biologics Evaluation and Research: convergence toward a unified database.
    Smith JK
    AAPS J; 2013 Apr; 15(2):388-94. PubMed ID: 23269527
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Early Developments in the Regulation of Biologics.
    Coleman TS
    Food Drug Law J; 2016; 71(4):544-607. PubMed ID: 29140646
    [TBL] [Abstract][Full Text] [Related]  

  • 15. United States Food and Drug Administration Regulation of Gene and Cell Therapies.
    Bailey AM; Arcidiacono J; Benton KA; Taraporewala Z; Winitsky S
    Adv Exp Med Biol; 2015; 871():1-29. PubMed ID: 26374210
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Regulation and abuse liability testing of medicines in Europe beyond 1992.
    García Alonso F
    Br J Addict; 1991 Dec; 86(12):1533-6. PubMed ID: 1786483
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Evaluating the abuse potential of psychedelic drugs as part of the safety pharmacology assessment for medical use in humans.
    Heal DJ; Gosden J; Smith SL
    Neuropharmacology; 2018 Nov; 142():89-115. PubMed ID: 29427652
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Human Abuse Liability Assessment of Tobacco and Nicotine Products: Approaches for Meeting Current Regulatory Recommendations.
    Vansickel A; Baxter S; Sherwood N; Kong M; Campbell L
    Nicotine Tob Res; 2022 Feb; 24(3):295-305. PubMed ID: 34498698
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Perspectives and future on testing for abuse liability in humans.
    Camí J
    Br J Addict; 1991 Dec; 86(12):1529-31. PubMed ID: 1786482
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Principles of laboratory assessment of drug abuse liability and implications for clinical development.
    Carter LP; Griffiths RR
    Drug Alcohol Depend; 2009 Dec; 105 Suppl 1():S14-25. PubMed ID: 19443137
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.